Publishing in black and white: the relevance of listing of scientific journals
Publishing in black and white: the relevance of listing of scientific journals
复制标题
DOI：
10.1007/s00296-017-3830-2
复制
发表时间：
2017-11-01
影响因子：
4
通讯作者：
Negi, Vir Singh
中科院分区：
文献类型：
--
作者：
Misra, Durga Prasanna;Ravindran, Vinod;Negi, Vir Singh
科学出版，包括流变学领域的出版，正在迅速发展。掠夺性期刊是当代出版业的主要威胁之一，特别是对渴望和天真的作者。在这篇叙述性综述中，我们讨论了作者可以用来将真正的科学期刊列入白色名单和将"掠夺性"期刊列入黑名单的机制。将期刊纳入Medline（但不仅仅是Pubmed），Web of Science，Scopus或Embase等知名指数会提高期刊真实性的可能性，如果它被纳入当前的期刊引文报告中，则更是如此。也存在其他商业上可用的白名单，一些国家的监管机构也发布了白名单。自从非常有用的Beall黑名单失效后，一个商业上可用的黑名单出现了。在无法进入白名单或黑名单的情况下，某些特征，如反复通过电子邮件征求来自未知来源的期限极短的文章，未被列入知名指数，期刊未被国家或国际社会出版或认可，以及目前出版的文章稀缺，应使作者怀疑期刊的真实性质。各国学会应共同努力，生成特定主题（包括特定流变学）的白名单，供世界各地的作者免费使用。
Scientific publishing, including in the field of Rheumatology, is evolving rapidly. Predatory journals are one of the major threats to contemporary publishing, especially to eager and na < ve authors. In this narrative review, we discuss mechanisms that authors can employ to white list genuine scientific journals and blacklist "predatory" ones. Inclusion of a journal in reputed indices such as Medline (but not just Pubmed), Web of Science, Scopus or Embase raises the likelihood that the journal is genuine, more so if it is included in the current Journal Citation Reports. Other commercially available whitelists also exist, so also whitelists published by regulatory authorities in some countries. A commercially available blacklist has emerged since the very useful Beall's blacklist became defunct. In the absence of access to a whitelist or blacklist, certain characteristics such as repeated email solicitations for articles with an extremely narrow deadline from unknown sources, lack of inclusion in reputed indices, journals not published or endorsed by national or international society and scarcity of currently published articles should render authors suspicious of the genuine nature of a journal. National societies should work together to generate subject-specific (including Rheumatology specific) whitelists that can be available free of cost to authors from all over the world.